This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schmittgen, T. D. Articles by Au, J. L-S. Search for Related Content PubMed PubMed Citation Articles by Schmittgen, T. D. Articles by Au, J. L-S.

Pharmacodynamics of Mitomycin C in Cultured Human Bladder Tumors¹

College of Pharmacy [T. D. S., J. L-S. A.] and Division of Urology [M. G. W., R. A. B.], The Ohio State University, Columbus, Ohio 43210

The effects of mitomycin C (MMC) concentration and exposure time on the inhibition of tumor cell labeling index (LI) were studied using surgical bladder tumor samples from 14 patients. The bladder tumors were cultured as 1-mm³ fragments on collagen gels. LI was determined by incorporation of [³H]thymidine and autoradiography. All tumors responded to MMC. However, the sensitivity varied significantly between tumors. At a 2-h exposure, the concentrations required for 50 and 90% inhibition (IC₅₀ and IC₉₀) ranged from 0.237 to 14.9 and 2.76 to 74.5 µg/ml, respectively. There was an inverse correlation between MMC activity and tumor LI; the IC values were higher for the more rapidly proliferating tumors. Exposure time had a pronounced effect on MMC activity. Shortening the exposure time from 2 to 0.5 h increased the IC₅₀ 3-fold, while prolonging the exposure time from 2 to 24 h decreased the IC₅₀ 6-fold. To determine the minimum concentration and exposure time necessary to reduce tumor LI by 90%, the data for 6 tumors were computer fitted to the pharmacodynamic relationship Cⁿ x T = k. The analysis showed that, on average, a 2.5-h exposure of 3 µg/ml was needed for 50% inhibition and a 7-h exposure of 8 µg/ml was needed for 90% inhibition. A comparison of the IC values of MMC determined in this study with the literature values determined using monolayer and spheroid cultures of established human bladder tumor cell lines showed that the drug activity in cultured tumor fragments ranged from 7- to 5300-fold lower than that in established cell lines. In summary, our data demonstrate a heterogeneity in the response of bladder tumors from individual patients to MMC, a decreased sensitivity to MMC with increasing tumor proliferation, and that drug concentration and exposure time are critical determinants of MMC activity.

¹ Supported in part by research Grant RO1 CA-49816 and a Research Career Development Award for J. L-S. Au (K04 CA-01497) from The National Cancer Institute, NIH, Department of Health and Human Services. T. D. S. was supported in part by a fellowship from The Berlex Corporation. The Ohio State University Cooperative Human Tissue Network was supported by Grant 2UO1 CA-44971-04 from The National Cancer Institute, NIH, Department of Health and Human Services.

² To whom requests for reprints should be addressed, at 500 West 12th Avenue, the Ohio State University, Columbus, OH 43210.

Received 3/21/91. Accepted 5/17/91.

This article has been cited by other articles:

				B. A. Hadaschik, H. Adomat, L. Fazli, Y. Fradet, R. J. Andersen, M. E. Gleave, and A. I. So Intravesical Chemotherapy of High-Grade Bladder Cancer with HTI-286, A Synthetic Analogue of the Marine Sponge Product Hemiasterlin Clin. Cancer Res., March 1, 2008; 14(5): 1510 - 1518. [Abstract] [Full Text] [PDF]

				L. Hu, J. L-S. Au, and M. G. Wientjes Computational Modeling to Predict Effect of Treatment Schedule on Drug Delivery to Prostate in Humans Clin. Cancer Res., February 15, 2007; 13(4): 1278 - 1287. [Abstract] [Full Text] [PDF]

				J. F. Granada, D. Ensenat, A. N. Keswani, G. L. Kaluza, A. E. Raizner, X.-m. Liu, K. J. Peyton, M. A. Azam, H. Wang, and W. Durante Single Perivascular Delivery of Mitomycin C Stimulates p21 Expression and Inhibits Neointima Formation in Rat Arteries Arterioscler. Thromb. Vasc. Biol., November 1, 2005; 25(11): 2343 - 2348. [Abstract] [Full Text] [PDF]

				Z. Lu, T.-K. Yeh, M. Tsai, J. L.-S. Au, and M. G. Wientjes Paclitaxel-Loaded Gelatin Nanoparticles for Intravesical Bladder Cancer Therapy Clin. Cancer Res., November 15, 2004; 10(22): 7677 - 7684. [Abstract] [Full Text] [PDF]

				J. L.-S. Au and M.G. Wientjes Re: metabolites of a tobacco-specific lung carcinogen in nonsmoking women exposed to environmental tobacco smoke. J Natl Cancer Inst, October 17, 2001; 93(20): 1575 - 1577. [Full Text] [PDF]

				Y. Gan, Y. Mo, J. E. Kalns, J. Lu, K. Danenberg, P. Danenberg, M. G. Wientjes, and J. L-S. Au Expression of DT-Diaphorase and Cytochrome P450 Reductase Correlates with Mitomycin C Activity in Human Bladder Tumors Clin. Cancer Res., May 1, 2001; 7(5): 1313 - 1319. [Abstract] [Full Text]

				J. L.-S. Au, R. A. Badalament, M. G. Wientjes, D. C. Young, J. A. Warner, P. L. Venema, D. L. Pollifrone, J. D. Harbrecht, J. L. Chin, S. P. Lerner, et al. Methods to Improve Efficacy of Intravesical Mitomycin C: Results of a Randomized Phase III Trial J Natl Cancer Inst, April 18, 2001; 93(8): 597 - 604. [Abstract] [Full Text] [PDF]

				M.-L. Li, L. Horn, P. S. Firby, and M. J. Moore Pharmacological Determinants of 9-Aminocamptothecin Cytotoxicity Clin. Cancer Res., January 1, 2001; 7(1): 168 - 174. [Abstract] [Full Text]

				S. M. Di Stasi, A. Giannantoni, R. Massoud, S. Dolci, P. Navarra, G. Vespasiani, and R. L. Stephen Electromotive versus Passive Diffusion of Mitomycin C into Human Bladder Wall: Concentration-Depth Profiles Studies Cancer Res., October 1, 1999; 59(19): 4912 - 4918. [Abstract] [Full Text] [PDF]